CN101671669B - Hepatocellular carcinoma targeting gene expression element AE and applications thereof - Google Patents
Hepatocellular carcinoma targeting gene expression element AE and applications thereof Download PDFInfo
- Publication number
- CN101671669B CN101671669B CN2009101018158A CN200910101815A CN101671669B CN 101671669 B CN101671669 B CN 101671669B CN 2009101018158 A CN2009101018158 A CN 2009101018158A CN 200910101815 A CN200910101815 A CN 200910101815A CN 101671669 B CN101671669 B CN 101671669B
- Authority
- CN
- China
- Prior art keywords
- cell
- gene
- expression element
- expression
- afp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention provides a hepatocellular carcinoma targeting gene expression element AE and applications thereof, and the gene expression element AE has a nucleotide sequence indicated in SEQ ID No.1. After the expression element AE is guided into Alpha-fetoprotein positive tumor cells, the artificial microRNA aiming at eukaryotic initiation factor 4E can be expressed in the cell and the expression of the eukaryotic initiation factor 4E in the cell can be effectively inhibited, the formation of the integrated translation initiation complex in the cell is further affected; and the synthesis of the protein is blocked finally, the growth and multiplication of the AFP positive hepatoma cell are specially inhibited and the expression element AE can be applied to the preparation of the targeting gene curing medicine of AFP positive liver cancer.
Description
Technical field
The invention belongs to biotechnology; Relate to gene expression regulation; Specifically; Relate to a specific specificity can suppress eukaryotic cell translation initiation factor 4E in the liver cancer cell effectively to design, the preparation of the targeted gene expression element AE of alph-fetoprotein positive liver cancer and after specifically expressing, its transcription product are processed in the liver cancer cell of alph-fetoprotein positive in cell expression; Protein synthesis new in the cell can't be carried out because of complete eukaryotic cell translation initiation complex lacks, thereby reach the effect that suppresses liver cancer cell growth and propagation.The present invention can be used for preparing target property therapy of tumor medicine.
Background technology
Malignant tumour is human at present mainly one of " killer ", the change of Along with people's mode of life and environment in recent years, and its sickness rate is in rising trend, has become first cause of death in many cities, is at the second place in the rural area.Liver cancer is one of modal very harmful malignant tumour in China, compares with other common cancers such as lung cancer, gastroenteric tumor, breast cancers, and the curative effect and the prognosis of usual manners such as present operation and chemotherapy are all undesirable.
The biotherapy that is called as the oncotherapy new model is just demonstrating more and more good prospects for application at present.In various tumor biotherapy means; Gene therapy is a main direction all the time, China development first formally gets into the genomic medicine of clinical use, promptly is its representative to the adenovirus injection liquid " Gendicine " cancer suppressor gene p53, that can express wild type p53 of undergoing mutation in many tumour cells in the world.Along with the develop rapidly of Medical Molecular Biology technology and knowledge, various advanced persons' molecular biology method all applies in the genetic treatment of tumor research.But because the incidence and development of tumour relates to numerous genes; And present research is mostly only to indivedual target genes; Therefore, press down the knurl effect though these researchs all demonstrate in the body of external tumor killing effect even tumor animal model of cell levels preferably, actual effect is unsatisfactory.Therefore, explore, attempt new therapy of tumor means and have crucial meaning.
Normal cell changes under the effect of various carcinogenic factors until last generation canceration gradually, has considerable gene to show the phenomenon of over-expresses, and especially some promote the overexpression of malignant phenotypes' such as cell growth, invasion and attack gene.To the gene of unconventionality expression in the tumour, people have designed the method for many targeting gene therapies, and the research that wherein promotes Expression of Related Genes such as tumor growth, invasion and attack with sealing is a quite popular field.In a large amount of in the past research; People utilize sense-rna (antisense RNA) that the tumour cell cance high-expression gene is sealed; But because the restriction that sense-rna itself exists; Though this type research has obtained bigger achievement at aspects such as suppressing growth of tumour cell, the migration of control cell invasion, the effect of its sealing genetic expression is still undesirable.
SiRNA (small interfering RNA, siRNA) be found to be that expression of gene provides a strong instrument in the human intervention cell.Utilize the siRNA of the double chain form of chemosynthesis; Or drive little hair fastener appearance RNA (the small hairpin RNA of the similar transcribe by III type promotor; ShRNA); Can pass through sequence-specific matching principle degraded target gene, thereby target gene expression is effectively suppressed, therefore also attempted being applied to gene therapy.But because the siRNA cost of chemosynthesis is too high, and the expression of shRNA is unfavorable for regulation and control, and these factors have limited this The Application of Technology widely.
Microrna (microRNA) is naturally occurring a kind of microRNA in the cell; It is a kind of important way that level is carried out expression regulation after genetic transcription; Target gene mRNA can degrade under the situation that sequence is mated fully; Also can under the situation of the non-coupling fully of sequence, suppress the translation of target gene; Be a research focus in the present life science, aspect the relevant microRNA of tumour big quantity research arranged also, and mostly concentrating on discovery and the Function Identification of expressing discrepant various natural microRNA between normal cell and the tumour cell.
Because natural microRNA is driven by II type promotor to transcribe; If so microRNA molecule like the artificial design class; Also should transcribe by the guiding of II type promotor; Can regulate and control and the characteristics of II type promotor are its transcripting starting functions, so the expression of the artificial mi RNA in its downstream should receive artificial control, and some nearest bibliographical informations of the mode of action of microRNA have confirmed this imagination.
In the present invention we to select this important step of protein synthesis of cell be target spot, design the sequence of artificial microRNA, the expression of the key protein in the arrestin matter building-up process stops through synthetic cell growth and the propagation of making of blocking protein.Because proteinic synthesizing is the process of a complicacy and accurate regulation and control; Need be incorporated into rrna, start proteinic translation by the initiation complex guiding mRNA that tens eukaryotic cell translation initiation factors are formed; Wherein eukaryotic cell translation initiation factor 4E is responsible for combining the 5 ' cap structure of mRNA; Has important effect; Therefore will effectively block the intracellular protein synthetic to the inhibition of eukaryotic cell translation initiation factor 4E and start, thereby make cell stop new protein synthesis, and then suppress the growth and the propagation of cell because of lacking complete translation initiation complex.
In order to reach target property effect to tumour cell; To China occurred frequently, high, the curative effect of grade malignancy and all relatively poor this knurl kind of liver cancer of prognosis; Be utilized in do not express in the normal cell but in liver cancer cell the liver cancer cell specificity ALPHA-FP (alpha-fetoprotein of high expression level; AFP) characteristics, the expression regulation sequence of the AFP upstream region of gene of having recombinated is used for the expression of microRNA of artificial design.This gene expression element does not have any expression after importing normal cell; And after importing AFP male liver cancer cell; Can give expression to corresponding microRNA and block the protein synthesis in the liver cancer cell effectively, thereby reach the growth of target property inhibition liver cancer cell.
Based on thinking of the present invention; Can also carry out the design of artificial microRNA as target sequence with other site of eukaryotic cell translation initiation factor 4E gene; Or carry out the cell protein synthetic with other important gene in the cell protein route of synthesis as target gene and block, and then cell growth inhibiting and propagation.
Summary of the invention
A kind of hepatocellular carcinoma targeting gene expression element AE that the purpose of this invention is to provide is a kind of dna molecular, has the nucleotide sequence shown in the SEQ ID No:1.Wherein the 7th to the 827th is the-4113 to the-3292 at human a-fetoprotein (AFP) the genetic transcription starting point upper reaches, and a plurality of enhancement factor and HNF binding sites of transcribing are contained in this zone; The 831st to the 1012nd is the-182 to the-1 at human a-fetoprotein (AFP) the genetic transcription starting point upper reaches, and the basic promoter function of AFP is contained in this zone; The AFP positive cell expression regulation sequence of forming reorganization from the 1st to the 1012nd 1012bp fragment; The 1019th to the 1828th microRNA that the manual work to people's eukaryotic cell translation initiation factor 4E gene that is 6 series connection connect designs; The 1829th to the 2177th is bovine growth hormone gene polyadenylic acid signaling zone, for genetic expression provides transcription termination signal.
Another object of the present invention provides the application of this Expression element AE in the target gene therapy medicine of preparation ALPHA-FP (AFP) male liver cancer.This Expression element AE is after importing AFP male tumour cell; Can in cell, express artificial microRNA to eukaryotic cell translation initiation factor 4E; And effectively suppress the expression of eukaryotic cell translation initiation factor 4E in the cell; And then having influence on the formation of translation initiation complex complete in the cell, final blocking protein is synthetic, cell growth inhibiting and propagation.
This Expression element AE can make up the targeting gene therapy pharmaceutical carrier, is used for the target gene therapy of AFP male liver cancer.Recombinant AFP expression regulation element in this Expression element can be used for regulating and control other expression of gene, can be used for other expression vector to the artificial microRNA sequence of people's eukaryotic cell translation initiation factor 4E reaches the expression purpose that inhibitory phase is answered cell eukaryotic cell translation initiation factor 4E.
The present invention compares with prior art and has the following advantages and effect: the gene therapy medicament that utilizes Expression element provided by the invention to prepare; Its characteristics be with the embryonal antigen AFP that liver cancer cell specificity is expressed be tumor cell specific expression regulation means, with tumour cell fast in the required protein synthesis of growth in the required translation initiation complex key protein eukaryotic cell translation initiation factor 4E be that action target spot carries out expression inhibiting; It is synthetic to block intracellular protein effectively, suppresses the growth and the propagation of AFP male liver cancer cell specifically.
Description of drawings
Fig. 1 is that recombinant AFP positive cell expression regulation sequence makes up PCR product electrophorogram.
Fig. 2 makes up PCR product electrophorogram for the artificial microRNA to eukaryotic cell translation initiation factor 4E.
Fig. 3 cuts the evaluation electrophorogram for the pDC312-AE enzyme.
Fig. 4 is that Western blot method detects the inhibition that AE expresses eukaryotic cell translation initiation factor 4E.
Fig. 5 is the mtt assay detected result.
Embodiment
The present invention combines accompanying drawing and specific embodiment to be described further.These embodiment only are used for explanation, but do not limit the present invention.
Embodiment 1:
The clone of recombinant AFP positive cell expression regulation sequence
At first obtain mRNA sequence (the GenBank accession number: NM_001134) of people AFP gene from the GenBank retrieval; And then the online genome compare of analysis method of warp obtains No. 4 chromosomal genome sequence (the GenBank accession number: NT_006216.14) that the people comprises the AFP gene from GenBank; And be benchmark with AFP gene mRNA sequence; With its 5 ' end as AFP genetic transcription starting point; Genome sequence design synthetic primer 1:5 '-AGA TCT CAG ATT GAA TTA TTTGCC TGT CA-3 ', primer 2 according to its upper reaches: 5 '-GGA TCC TAG GAA GTT TTC GCA ATA ATAC-3 ', primer 3:5 '-AGATCT GCC CCA AAG AGC TCT GTG T-3 ' and primer 4:5 '-GGATCC AAA TCA TGC TGA AAT TCT TTT ATA CTC-3 '; Utilize polymerase chain reaction technique (Polymerase Chain Reaction, PCR) genomic dna with human liver cancer cell SMMC7721 is a template, carries out nucleic acid amplification (primer 1 and primer 2, primer 3 and primer 4) with above-mentioned primer; Obtain amplified production A (821bp) and B (180bp); Referring to Fig. 1, wherein swimming lane 1,4 is 1kb DNA Ladder; Swimming lane 2 is amplified production A (821bp), and swimming lane 3 is amplified production B (180bp).
Amplified production A, B are cloned into pGEM T-easy carrier (Promega company, the U.S.) respectively with T-A clone's mode, through determined dna sequence and with its exactness of genome sequence (NT_006216.14) check verify.Then A is connected to the Bgl II site of the 5 ' end of B behind restriction enzyme BamH I and Bgl II double digestion, becomes the AFP positive cell expression regulation sequence of reorganization.
Embodiment 2:
Clone to the artificial microRNA of people's eukaryotic cell translation initiation factor 4E
Obtain mRNA sequence (the GenBank accession number: NM_001968) of people's eukaryotic cell translation initiation factor 4E gene from the GenBank retrieval; Utilize suitable site on this mRNA sequence of online software analysis; Confirm the action target spot of artificial microRNA, design synthetic primer 1:5 '-TGC TGT TGA CAGTGA GCG CGG AGC ACT AGT TTG ATT ATT ATA GTG AAG CCA CAG ATGTA-3 ', primer 2: 5 '-TCC GAG GCA GTA GGC ATG GAG CAC TAG TTT GATTAT TAT ACA TCT GTG GCT TCA CTA TA-3 ', primer 3:5 '-AGA TCT GAT CCAAGA AGG TAT ATT GCT GTT GAC AGT GAG CG-3 ' and primer 4:5 '-GGA TCCATC GTA GCC CTT GAA GTC CGA GGC AGT AGG CA-3 '.Earlier primer 1 and primer 2 are carried out overlapping extension PCR; Obtaining the amplified production C of 97bp, is template with this amplified production C again, carries out pcr amplification with primer 3 and primer 4; Obtain the amplified production D of 142bp; Referring to Fig. 2, wherein swimming lane 1 is DL2000 DNA Ladder, and swimming lane 2 is amplified production D (142bp).
Mode with the T-A clone is cloned into pGEM T-easy carrier, through its exactness of dna sequencing checking.This promptly is directed against the artificial microRNA sequence of people's eukaryotic cell translation initiation factor 4E.In order to strengthen its action effect, the BamH I site with reclaiming this manual work microRNA sequence and insert identical carrier again behind restriction enzyme BamH I and the BglII double digestion obtains 6 artificial microRNA sequences that are connected in series.
Embodiment 3:
The structure of hepatocellular carcinoma targeting gene expression element AE and the preparation of adenovirus carrier
At first make up the pDC312-BGHpA carrier: with adenovirus shuttle plasmid pDC312 carrier (Microbix company; The U.S.) open with restriction enzyme Xba I single endonuclease digestion; Mend flatly with the Klenow enzyme, use restriction enzyme HindIII single endonuclease digestion again, remove Xba I to the part between the HindIII (from HindIII, Sac I, Ecl136II, Acc I, Sal I to Xba I); Recovery part one end is a flush end, and the other end is the HindIII sticky end.PcDNA3.1 (+) carrier (Invitrogen company; The U.S.) with restriction enzyme Pvu II and HindIII double digestion; Recovery comprises the fragment of HindIII, Asp718, Kpn I, BamH I, BstXI, EcoR I, EcoRV, BstXI, Not I, Xho I, Xba I, Dra II, Apa I and Pme I MCS and ox growth factor gene polyadenylic acid signal (BGHpA); One end is the HindIII sticky end, and the other end is the flush end of PvuII.Above-mentioned two fragments are coupled together, the pDC312-BGHpA carrier, can on MCS, insert promotor and goal gene coding region.
Again the recombinant AFP positive cell expression regulation sequence among the embodiment 1 is reclaimed after with restriction enzyme BamH I and Bgl II double digestion from carrier; And the BamH I site of inserting pDC312-BGHpA, obtain having the adenovirus shuttle plasmid of recombinant AFP positive cell expression regulation sequence and BGHpA.At last with 6 reclaiming after from carrier of being connected in series with restriction enzyme BamH I and Bgl II double digestion to the artificial microRNA sequences of people's eukaryotic cell translation initiation factor 4E; Insert the BamH I site of this shuttle plasmid; Obtain having the adenovirus shuttle plasmid of complete hepatoma targeting character Expression element AE; Enzyme is cut qualification result and is conformed to fully with expection, and referring to Fig. 3, wherein swimming lane 1 is 1Kb Plus DNAMarker; Swimming lane 2 is cut through BamH I, Bgl I, EcoR I enzyme for pDC312-AE.
With above-mentioned adenovirus shuttle plasmid and adenovirus skeleton plasmid pBHGlox (delta) E1 that has complete hepatoma targeting character Expression element AE; 3cre (Microbix company; The U.S.) cotransfection adenovirus packaging cell 293 cells obtain having the adenovirus carrier of Expression element AE.
Embodiment 4:
Gene expression element AE is to the target property inhibition of AFP masculine liver cancer cell
A, Western blot method detect the inhibition that AE expresses eukaryotic cell translation initiation factor 4E
The AFP male liver cancer cell Hep3B cell of taking the logarithm vegetative period is by 3 * 10
5The density of cells/well is inoculated in 6 orifice plates, cultivates to make it adherent and reach 80% degree of converging in 24 hours.With the above-mentioned adenovirus that has Expression element AE of substratum dilution, (multiplicity of infection is 100pfu/cell and 10pfu/cell cells infected MOI), termination effect behind the 48hr with infection multiplicity; Extract total protein of cell, carry out SDS-polyacrylamide gel electrophoresis (10% separation gel, 5% concentrates glue); Then albumen is gone to pvdf membrane, sealing back and the monoclonal antibody (SantaCruz Biotechnology, the Inc. that dilute anti-eukaryotic cell translation initiation factor 4E at 1: 1000; The U.S., eIF4E (P-2): sc-9976) combine, behind the room temperature 2hr; Wash film 3 times with TBST, combine the anti-mouse IgG antibody of HRP mark (Bioisystech Co., Ltd of China fir Golden Bridge in Beijing) again, wash film once more; Use chemical luminescence reagent kit (Roche company, the U.S.) to develop X-ray sheet exposure then.With GAPDH is internal reference, with the same combination of GAPDH antibody (go up the Haikang and become Bioisystech Co., Ltd), development and the exposure of HRP mark.The band green fluorescent protein is established in experiment, and (greenfluorescent protein, adenovirus infection GFP) compares with the cell of no adenovirus infection.The result shows that referring to Fig. 4 the eukaryotic cell translation initiation factor 4E expression among the AFP masculine liver cancer cell Hep3B that infects the adenovirus that has Expression element AE obviously is suppressed.G among the figure: eukaryotic cell translation initiation factor 4E expressed after band AE adenovirus MOI was respectively 100 and 10 infection Hep3B liver cancer cells; GFP: eukaryotic cell translation initiation factor 4E expressed after band GFP adenovirus MOI was respectively 100 and 10 infection Hep3B liver cancer cells; N: do not infect that eukaryotic cell translation initiation factor 4E expresses in the Hep3B liver cancer cell of adenovirus.
B, in-vitro cell growth inhibition test (mtt assay)
The liver cancer cell Hep3B that takes the logarithm vegetative period, HepG2, SMMC7721 and breast cancer cell Bcap37 (non-liver cancer cell) are by 2 * 10
3The density of cells/well is inoculated in 96 orifice plates, cultivates to make it adherent in 24 hours.With the adenovirus of band AE is 200pfu/cell, 100pfu/cell, 50pfu/cell, 10pfu/cell, 1pfu/cell and 0pfu/cell cells infected with MOI.After 4 days, every hole adds MTT solution (5mg/ml) 20ul at virus infection, and 37 ℃ are continued to cultivate 4hr, end to cultivate.Discard culture supernatant liquid, every hole adds DMSO 200ul, and vibration 10min fully dissolves crystallisate, on enzyme-linked immunosorbent assay instrument, measures each hole 570nm wavelength OD value.Cell survival rate=(not effect group of virus function group OD value/virus OD value) * 100%.Set up 5 multiple holes, repeat 3 times for every group.As can beappreciated from fig. 5, the adenovirus of the band AE of different MOI all has inhibition in various degree to the growth of different liver cancer cell Hep3B, HepG2 and SMMC7721, and Bcap37 does not then have obvious inhibition to breast cancer cell (non-liver cancer cell).
The sequence that the present invention relates to
< 120>a kind of hepatocellular carcinoma targeting gene expression element AE and application thereof
<160>9
<210>1
<211>2177
<212>DNA
< 213>artificial sequence
<220>
< 223>alph-fetoprotein positive liver cancer cell specificity Expression element AE sequence
<400>1
DNASIS
SEQ
agatctcaga?ttgaattatt?tgcctgtcat?acagctaata?attgaccata?agacaattag?60
atttaaatta?gttttgaatc?tttctaatac?caaagttcag?tttactgttc?catgttgctt?120
ctgagtggct?tcacagactt?atgaaaaagt?aaacggaatc?agaattacat?caatgcaaaa?180
gcattgctgt?gaactctgta?cttaggacta?aactttgagc?aataacacat?atagattgag?240
gattgtttgc?tgttagtata?caaactctgg?ttcaaagctc?ctctttattg?cttgtcttgg?300
aaaatttgct?gttcttcatg?gtttctcttt?tcactgctat?ctatttttct?caaccactca?360
catggctaca?ataactgtct?gcaagcttat?gattcccaaa?tatctatctc?tagcctcaat?420
cttgttccag?aagataaaaa?gtagtattca?aatgcacatc?aacgtctcca?cttggagggc?480
ttaaagacgt?ttcaacatac?aaaccgggga?gttttgcctg?gaatgtttcc?taaaatgtgt?540
cctgtagcac?atagggtcct?cttgttcctt?aaaatctaat?tacttttagc?ccagtgctca?600
tcccacctat?ggggagatga?gagtgaaaag?ggagcctgat?taataattac?actaagtcaa?660
taggcataga?gccaggactg?tttgggtaaa?ctggtcactt?tatcttaaac?taaatatatc?720
caaaactgaa?catgtactta?gttactaagt?ctttgacttt?atctcattca?taccactcag?780
ctttatccag?gccacttatt?tgacagtatt?attgcgaaaa?cttcctagga?tctgccccaa?840
agagctctgt?gtccttgaac?ataaaataca?aataaccgct?atgctgttaa?ttattggcaa?900
atgtcccatt?ttcaacctaa?ggaaatacca?taaagtaaca?gatataccaa?caaaaggtta?960
ctagttaaca?ggcattgcct?gaaaagagta?taaaagaatt?tcagcatgat?ttggatctga?1020
tccaagaagg?tatattgctg?ttgacagtga?gcgcggagca?ctagtttgat?tattatagtg?1080
aagccacaga?tgtataataa?tcaaactagt?gctccatgcc?tactgcctcg?gacttcaagg?1140
gctacgatgg?atctgatcca?agaaggtata?ttgctgttga?cagtgagcgc?ggagcactag?1200
tttgattatt?atagtgaagc?cacagatgta?taataatcaa?actagtgctc?catgcctact?1260
gcctcggact?tcaagggcta?cgatggatct?gatccaagaa?ggtatattgc?tgttgacagt?1320
gagcgcggag?cactagtttg?attattatag?tgaagccaca?gatgtataat?aatcaaacta?1380
gtgctccatg?cctactgcct?cggacttcaa?gggctacgat?ggatctgatc?caagaaggta?1440
tattgctgtt?gacagtgagc?gcggagcact?agtttgatta?ttatagtgaa?gccacagatg?1500
tataataatc?aaactagtgc?tccatgccta?ctgcctcgga?cttcaagggc?tacgatggat?1560
ctgatccaag?aaggtatatt?gctgttgaca?gtgagcgcgg?agcactagtt?tgattattat?1620
agtgaagcca?cagatgtata?ataatcaaac?tagtgctcca?tgcctactgc?ctcggacttc?1680
aagggctacg?atggatctga?tccaagaagg?tatattgctg?ttgacagtga?gcgcggagca?1740
ctagtttgat?tattatagtg?aagccacaga?tgtataataa?tcaaactagt?gctccatgcc?1800
tactgcctcg?gacttcaagg?gctacgatgg?atccactagt?ccagtgtggt?ggaattctgc?1860
agatatccag?cacagtggcg?gccgctcgag?tctagagggc?ccgtttaaac?ccgctgatca?1920
gcctcgactg?tgccttctag?ttgccagcca?tctgttgttt?gcccctcccc?cgtgccttcc?1980
ttgaccctgg?aaggtgccac?tcccactgtc?ctttcctaat?aaaatgagga?aattgcatcg?2040
cattgtctga?gtaggtgtca?ttctattctg?gggggtgggg?tggggcagga?cagcaagggg?2100
gaggattggg?aagacaatag?caggcatgct?ggggatgcgg?tgggctctat?ggcttctgag?2160
gcggaaagaa?ccagctg?2177
<210>2
<211>29
<212>DNA
< 213>artificial sequence
<220>
< 223>the AFP upper reaches expression regulation sequence amplification primers 1 that designs according to the AFP genome sequence
<400>2
agatctcaga?ttgaattatt?tgcctgtca?29
<210>3
<211>28
<212>DNA
< 213>artificial sequence
<220>
< 223>the AFP upper reaches expression regulation sequence amplification primers 2 that designs according to the AFP genome sequence
<400>3
ggatcctagg?aagttttcgc?aataatac?28
<210>4
<211>25
<212>DNA
< 213>artificial sequence
<220>
< 223>the AFP upper reaches expression regulation sequence amplification primers 3 that designs according to the AFP genome sequence
<400>4
agatctgccc?caaagagctc?tgtgt?25
<210>5
<211>33
<212>DNA
< 213>artificial sequence
<220>
< 223>the AFP upper reaches expression regulation sequence amplification primers 4 that designs according to the AFP genome sequence
<400>5
ggatccaaat?catgctgaaa?ttcttttata?ctc?33
<210>6
<211>59
<212>DNA
< 213>artificial sequence
<220>
< 223>to the artificial microRNA amplification primers 1 of eukaryotic cell translation initiation factor 4E gene design
<400>6
tgctgttgac?agtgagcgcg?gagcactagt?ttgattatta?tagtgaagcc?acagatgta?59
<210>7
<211>59
<212>DNA
< 213>artificial sequence
<220>
< 223>to the artificial microRNA amplification primers 2 of eukaryotic cell translation initiation factor 4E gene design
<400>7
tccgaggcag?taggcatgga?gcactagttt?gattattata?catctgtggc?ttcactata?59
<210>8
<211>41
<212>DNA
< 213>artificial sequence
<220>
< 223>to the artificial microRNA amplification primers 3 of eukaryotic cell translation initiation factor 4E gene design
<400>8
agatctgatc?caagaaggta?tattgctgtt?gacagtgagc?g?41
<210>9
<211>38
<212>DNA
< 213>artificial sequence
<220>
< 223>to the artificial microRNA amplification primers 4 of eukaryotic cell translation initiation factor 4E gene design
<400>9
ggatccatcg?tagcccttga?agtccgaggc?agtaggca?38
Claims (2)
1. hepatocellular carcinoma targeting gene expression element AE; Be a kind of dna molecular; Its nucleotide sequence is shown in SEQ ID No:1; Wherein the 7th to the 827th is the-4113 to the-3292 at the human a-fetoprotein gene transcripting start point upper reaches; A plurality of enhancement factor and HNF binding sites of transcribing are contained in this zone, and the 831st to the 1012nd is the-182 to the-1 at the human a-fetoprotein gene transcripting start point upper reaches, and the basic promoter function of ALPHA-FP is contained in this zone; The alph-fetoprotein positive cell expressing regulating and controlling sequence of forming reorganization from the 1st to the 1012nd 1012bp fragment; The 1019th to the 1828th microRNA that the manual work to people's eukaryotic cell translation initiation factor 4E gene that is 6 series connection connect designs, the 1829th to the 2177th is bovine growth hormone gene polyadenylic acid signaling zone, for genetic expression provides transcription termination signal.
2. the application of a kind of hepatocellular carcinoma targeting gene expression element AE according to claim 1 in the target gene therapy medicine of the liver cancer of preparation alph-fetoprotein positive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101018158A CN101671669B (en) | 2009-08-27 | 2009-08-27 | Hepatocellular carcinoma targeting gene expression element AE and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101018158A CN101671669B (en) | 2009-08-27 | 2009-08-27 | Hepatocellular carcinoma targeting gene expression element AE and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101671669A CN101671669A (en) | 2010-03-17 |
| CN101671669B true CN101671669B (en) | 2012-05-02 |
Family
ID=42019092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101018158A Expired - Fee Related CN101671669B (en) | 2009-08-27 | 2009-08-27 | Hepatocellular carcinoma targeting gene expression element AE and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101671669B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2662358C2 (en) * | 2012-07-20 | 2018-07-25 | Президент Энд Феллоуз Оф Гарвард Колледж | Cell based quality control bioassays for nutriceutical and medicinal products |
| CN104611334B (en) * | 2015-01-19 | 2017-08-08 | 浙江省医学科学院 | A kind of gene expression element and its application for being used to suppress growth of tumour cell |
| DE102017103383A1 (en) * | 2017-02-20 | 2018-08-23 | aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) | System and method for cell-type specific translation of RNA molecules in eukaryotes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852979A (en) * | 2003-09-18 | 2006-10-25 | Isis药物公司 | Modulation of eIF4E expression |
| WO2008157688A2 (en) * | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
-
2009
- 2009-08-27 CN CN2009101018158A patent/CN101671669B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852979A (en) * | 2003-09-18 | 2006-10-25 | Isis药物公司 | Modulation of eIF4E expression |
| WO2008157688A2 (en) * | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
Non-Patent Citations (1)
| Title |
|---|
| 方向明等人.胃癌组织中e IF4E、VEGF和cyclinD1的表达及其意义.《世界华人消化杂志》.2008,第16卷(第2期),1304-1308. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101671669A (en) | 2010-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1640452A1 (en) | OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
| CN103789309B (en) | A kind of long-chain non-coding RNA lncRNA-BcrAR and the application in anti-cell canceration thereof | |
| CN107365785A (en) | The expression vector of NF kB activities and its regulation and control methods and applications in a kind of regulating cell | |
| CN107541513B (en) | Small interfering RNA (ribonucleic acid) for silencing CD317, recombinant vector, medicament and application thereof | |
| CN101671669B (en) | Hepatocellular carcinoma targeting gene expression element AE and applications thereof | |
| CN101671668B (en) | Hepatocellular carcinoma targeting gene expression element AG and applications thereof | |
| CN101671670B (en) | Hepatocellular carcinoma targeting gene expression element AP and applications thereof | |
| CN103173481A (en) | Plasmid vector containing 3'UTR (untranslated regions) sequence of ABCB1 gene and reporter gene as well as construction method and use of plasmid vector | |
| CN103484462B (en) | The recombinant adenoviral vector of Survivin promoter regulation CD gene builds and application | |
| CN104131034B (en) | A kind of chimeric vector and its preparation method and application | |
| CN101638655B (en) | Carcinoembryonic antigen positive cell targeted gene expression element CPE and application thereof | |
| CN101948544B (en) | FAT10 gene siRNA recombination analogue virus as well as preparation method and application thereof | |
| CN101638654A (en) | Carcinoembryonic antigen positive cell targeted gene expression element CPD and application thereof | |
| CN103173480A (en) | Method for screening multidrug resistance related microRNA (ribonucleic acid) by using dual-luciferase report genes | |
| CN108517335B (en) | A kind of Lentiviral and its construction method of liver cell miR-199b low expression | |
| CN104232685A (en) | Mouse model capable of monitoring NF (nuclear factor)-kB activity in liver by virtue of in-vivo imaging and construction method of mouse model | |
| CN105950655B (en) | The suicide gene HSVtk carrier for expression of eukaryon of Survivin promoter control | |
| CN102671215A (en) | Chitosan nanoparticle composite as well as preparation method and application thereof | |
| CN109022437A (en) | A kind of target site sequence and its application inhibiting the duplication of goat haemadsorption virus 1 | |
| CN102533828B (en) | Recombinant plasmid and virus of tissue specificity and application thereof. | |
| CN107937400A (en) | The small ribonucleic acid molecules of silence NS1 gene expressions and screening technique and application | |
| CN101892226A (en) | Small interfering RNA (siRNA) for restraining ACC gene expression of human adipocyte and expression vector and application thereof | |
| CN104611334B (en) | A kind of gene expression element and its application for being used to suppress growth of tumour cell | |
| CN102703451B (en) | Expression box for inhibiting expression of Bcl12 gene and vector containing expression box | |
| CN116162621A (en) | DNA double-strand sequence and application thereof, and lung adenocarcinoma cell proliferation inhibitor or lung adenocarcinoma drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 Termination date: 20150827 |
|
| EXPY | Termination of patent right or utility model |